Exchange: NASDAQ·Updated 02:37 PM EST
SPRO logo

SPRO Spero Therapeutics Inc

$0.8804
$0.0209
(2.32%)
Today
Reported EarningsNov 12
Mkt Cap$52.51M
Vol212,619.00

About SPRO

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
40

Bearish Sentiment

How do you feel about SPRO?

Quantumup
Cantor🏁 $SPRO Overweight-$6 and said--Spero is a clinical-stage biopharmaceutical company developing SP001 (anti-CD40L mAb), with its lead indication in IgG4-Related Disease (IgG4-RD). [IVBIY IVBXF AMGN IMVT ZBIO BMY SNY ARGX [GSK]] Previously, Spero developed therapies in the antibiotic space. This summer, it shifted into I&I by licensing SP001 from Innovent Biologics (NC). Spero will be investigating SP001 for the treatment of IgG4-RD (Phase 2 study starting in 2Q27) while Innovent investigates the same drug for the treatment of Sjögren's disease in China (Phase 2 study starting in early 2027). We believe investors have yet to pick up on this new strategy, making SPRO an under-the-radar stock.
6
DDel
$SPRO $GSK top experience and credentials of Dr. Ho, a fine director add to bod's by ceo. partner, GSK will do very well with tebi sales, royalties for Spro, and GSK get EMA tebi appr too, likely in early '27. added more spro on the dip.
4
G101SPM
$SPRO $1.14 ask. BUY/ADD 5X TO LONG POSITION. DAC (Dollar average cost oincludes this addition) (17) $1.57. BRIEF: Spero Therapeutics (SPRO) initiated at Overweight at Cantor Fitzgerald, tgt $6
4
Longbuy1
$SPRO 51MIL milestone payment to get the ball rolling anyday. At a market cap of 59mil price isn't factored in.
3
Longbuy1
$SPRO the 45M loss, 35M was for a one time licensing payment. So burn is about 10M a qtr. Utebzi could be bringing into 15M a qtr (35%). By the end of next year, putting them in net positive cash flow.
2
DDel
$SPRO GSK partner up green on a red market day. a good harbinger of things to come....in a bacterial drug resistance urgent world.... there would be no tebi w/o GSK global leader.
2
focafoca99
$SPRO appointed Dr. William Ho to its board and noted Dr. Patrick Vink's resignation effective Nov 10.
1

Advertisement|Remove ads.